Landmark simvastatin trial for secondary progressive multiple sclerosis begins in the UK

A landmark Phase III trial for secondary progressive multiple sclerosis (SPMS), known as the MS-STAT2 trial, has begun in the UK. Researchers hope to determine whether simvastatin could be an effective treatment for the disease. Multiple sclerosis (MS) affects more than 100,000 people in the UK. If the symptoms of an individual with a relapsing form of MS get increasingly worse over a period of at least 6 months, they can be said to have developed SPMS. Simvastatin is currently utilized in the treatment of high cholesterol; however, a smaller study in the past has shown that treatment with simvastatin...